Literature DB >> 18682394

Coordinate activation of human platelet protease-activated receptor-1 and -4 in response to subnanomolar alpha-thrombin.

Frederick A Ofosu1, Lori Dewar, Sharon J Craven, Yingqi Song, Aisha Cedrone, John Freedman, John W Fenton.   

Abstract

We previously demonstrated that human platelets activated with SFLLRN release PAR-1 activation peptide, PAR-1-(1-41), even in the presence of hirudin. This observation suggests that during their activation, platelets generate a protease that activates PAR-1. In this study, PAR-1 and -4 activation peptides were detected 10 s after <or=1.0 nm alpha-thrombin, 10 microm SFLLRN, or 100 microm AYPGKF were added to platelets. When SFLLRN or AYGPKF were added to platelets, generation of PAR-1 and -4 activation peptides was complete at 10 s. Generation of both PAR-1 and -4 activation peptides in response to 1 nm alpha-thrombin was significantly inhibited by affinity-purified anti-PAR-1-(35-62) IgY, anti-PAR-4-(34-54) IgY, and by the specific PAR-1 antagonist BMS 200261, but not by the PAR-4 antagonist YD3. Effective inhibition of platelet aggregation in response to 1.0 nm alpha-thrombin occurred only in the presence of both anti-PAR span antibodies. We conclude that platelet activation initiated with <or=1.0 nm alpha-thrombin proceeds via simultaneous PAR-1 and -4 activation. Inhibiting the activation of either PAR inhibits activation of the other. Both PAR-1 and -4 activation must be inhibited to prevent platelet activation subsequent to thrombin binding to platelets. The more efficient generation of PAR activation peptides by platelets activated with SFLLRN or AYGPKF, compared with alpha-thrombin, indicates that a platelet-derived serine protease that is inactivated by soybean trypsin inhibitor propagates PAR-1 and -4 activation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18682394     DOI: 10.1074/jbc.M802237200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

1.  Know your APC.

Authors:  Enrico Di Cera
Journal:  Blood       Date:  2009-06-04       Impact factor: 22.113

2.  The roles and mechanisms of PAR4 and P2Y12/phosphatidylinositol 3-kinase pathway in maintaining thrombin-induced platelet aggregation.

Authors:  Chin-Chung Wu; Shih-Yun Wu; Chieh-Yu Liao; Che-Ming Teng; Yang-Chang Wu; Sheng-Chu Kuo
Journal:  Br J Pharmacol       Date:  2010-10       Impact factor: 8.739

3.  Association of thrombin generation potential with platelet PAR-1 regulation and P-selectin expression in patients on dual antiplatelet therapy.

Authors:  Roza Badr Eslam; Florian Posch; Irene M Lang; Thomas Gremmel; Beate Eichelberger; Cihan Ay; Simon Panzer
Journal:  J Cardiovasc Transl Res       Date:  2014-01-17       Impact factor: 4.132

4.  Protease-activated receptor (PAR) 1 and PAR4 differentially regulate factor V expression from human platelets.

Authors:  Matthew Duvernay; Summer Young; David Gailani; Jonathan Schoenecker; Heidi E Hamm; Heidi Hamm
Journal:  Mol Pharmacol       Date:  2013-01-10       Impact factor: 4.436

5.  Protease-activated receptor-mediated platelet aggregation in acute coronary syndrome patients on potent P2Y12 inhibitors.

Authors:  Patricia P Wadowski; Joseph Pultar; Constantin Weikert; Beate Eichelberger; Benjamin Panzer; Kurt Huber; Irene M Lang; Renate Koppensteiner; Simon Panzer; Thomas Gremmel
Journal:  Res Pract Thromb Haemost       Date:  2019-05-22

6.  Protease-activated receptor-mediated platelet aggregation in patients with type 2 diabetes on potent P2Y12 inhibitors.

Authors:  Benjamin Panzer; Patricia P Wadowski; Kurt Huber; Simon Panzer; Thomas Gremmel
Journal:  Diabet Med       Date:  2022-05-16       Impact factor: 4.213

Review 7.  Evaluation on potential contributions of protease activated receptors related mediators in allergic inflammation.

Authors:  Huiyun Zhang; Xiaoning Zeng; Shaoheng He
Journal:  Mediators Inflamm       Date:  2014-04-30       Impact factor: 4.711

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.